

Creating a new class of drugs to address incurable autoimmune diseases

PITCH VIDEO INVESTOR PANEL



enteleexo.com Irvine CA

Technology Science Moonshots Healthcare Bio Tech

OVERVIEW UPDATES WHAT PEOPLE SAY 8 ASK A QUESTION 1

Highlights

- 1 >\$1M raised to date, plus \$310k on the same terms
- 2 CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease
- 3 Targeting 25M affected by immune-mediated diseases in US, equal to ~\$150B in medical costs/year
- 4 Our intellectual property is patent-protected (patent owned by the Company)
- 5 Raising \$2M for pre-clinical product development and IND enabling animal studies

Our Team



Milad Riazifar CEO

Exosome biologist with 10+ years of experience in exosome research and clinical development. Led the first clinical trial using exosomes in autoimmune disease to treat Type 1 Diabetes.



Todd Schurr COO

Multidisciplinary engineer with biomanufacturing experience. His expertise in cGMP manufacturing and process automation are key to streamlining the regulatory approval process.



Cameron Taylor CTO



Cameron Taylor, CTO

Biomedical engineer with extensive experience in stem cell biology and protein engineering. His expertise in gene editing is key to the development of the technology platform.

Pitch



EXOSOMES PROVEN EFFECTIVE IN MS

Mouse Model of Multiple Sclerosis Demonstrates Exosome Efficacy in Treating Autoimmune Disease



2

THE FOUNDERS



Milad Riazifar, Ph.D.
CEO
Exosome Expert



Cameron Taylor, M.S.E.
CTO
Protein Engineer



Todd Schurr, B.S.
COO
Biomanufacturing



3

NEW DISCOVERIES HAVE MADE THIS POSSIBLE

Our Founder's Research Demonstrates the Potential of Exosomes as Therapeutics in Autoimmunity

- Exosomes were discovered to play a role in cell communication in 2007 by Jan Lötvall
 - Jan was Milad's Ph.D. Co-Advisor
- In 2017, Milad first proved the feasibility of exosomes as therapeutics in a Multiple Sclerosis Murine Model



- In 2018, Milad led the first clinical trial using exosomes in autoimmune disease to treat Type 1 Diabetes



STEM CELL EXTRACELLULAR Vesicles: Extended Messages of Regeneration


Milad Riazifar,^{1,2,3,4,5,6*} Egeet J. Pome,^{1,2,3,4,5,6*} Jan Lötvall,^{7*} and Weixin Zhao,^{1,2,3,4,5,6}



4

SPECIFICITY BY DESIGN

Proprietary Exosome Engineering Platform Enables Us to Target a Variety of Autoimmune Diseases



5

MASSIVE MARKET POTENTIAL

Exosome Stability Allows Us to Formulate the Final Product into Multiple Modalities



Autoimmune Disease Market Size



Eye Drop



Injectable



Topical



Inhalable



6

WE WILL START WITH EYE DISEASE

Targeting Ocular Inflammatory Conditions Will Enable the Quickest Path to Clinic


- Dry Eye Disease (DED) and Sjogren's Syndrome (SS) are similar diseases and have a combined market size of **\$8.3B**
- We can service **\$5.5B** of this market, treating **12.6M Americans**
- Entelexo can market additional pipeline projects being developed internally or license them out to Big Pharma
 - Psoriasis, MS, Rheumatoid Arthritis, GvHD and Transplantation, and Traumatic Brain Injury (TBI)



7


CHANGING THE WAY WE TREAT DISEASE

Novel Mechanism of Action Gives us an Advantage Over Current Therapies



RAPID PRODUCT SCREENING

Predictive Models Developed with Diseased Patient Cells



INTELLECTUAL PROPERTY

Comprehensive Filings Ensure Coverage of Technology and Licensing Opportunities


- PCT Application No. PCT/US2020/038816
 - Discloses engineering platform, **no blocking IP identified**
 - Claims deemed **novel** by International Searching Authority
- Provisional Application US 63/127,827
 - 20+ indications disclosed in detail
 - **Licensing opportunities**
 - Next-generation platform designs

**WILSON
SONSINI**

DISTINCT FROM THE COMPETITION


Our Technology Differentiates Us from Existing Exosome Engineering Competitors

CODIAK **EVOX**



- **Therapy Inside**
- **RNA, Gene Therapy**
- **Cancer, Rare Diseases**

ENTELEKO
BIOTHERAPEUTICS



- **Therapy Outside**
- **Ligands**
- **Autoimmune Diseases**

RAISING \$2M TO MEET MILESTONES



*The above slide contains forward-looking projections that are not guaranteed.

** A max of \$1.07M of the \$2M goal will be sourced from Wefunder



Downloads

[Entelexo MS Mouse.mp4](#)